Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

10 treatments under study, led by Danvatirsen

Research Leaders

9 sponsors active, led by The First Hospital of Jilin University

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Phase 2 (3)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05254899Phase 2Completed

A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

NCT03794544Phase 2Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NCT05149170Phase 2UnknownPrimary

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Showing all 3 trials

Research Network

Common Treatments

  • Danvatirsen1
  • Involved Site Radiotherapy1
  • Pegaspargase1
  • Durvalumab1
  • Antipd1 Monoclonal Antibody1

Active Sponsors

  • The First Hospital of Jilin University2
  • Peking University Cancer Hospital & Institute1
  • Chinese Academy of Medical Sciences1
  • The Affiliated Hospital Of Guizhou Medical University1
  • The First Affiliated Hospital of Dalian Medical University1

Top Investigators

Related Conditions

  • Extranodal Nktcell Lymphoma Nasal And Nasaltype1
  • Nsclc1
  • Highrisk Cancer1
  • Extranodal Nktcell Lymphoma1
  • Resectable1

Activity Timeline